New targets in psoriatic arthritis - Wikidata - awgldk - TriplyDB

New targets in psoriatic arthritis

New targets in psoriatic arthritis

http://www.wikidata.org/entity/Q28069592

about

New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.Advances in targeted therapy.

P2860

Q38768900-D2EE0725-BF1B-4753-B638-8C9EF13E2093 Q38825623-9F3E1799-4D6B-4AD9-98A2-72B12988960D Q48296840-D7EE04F1-49F7-4FC0-9A30-E1D4EC243579 Q53707988-526FF77A-4CA6-42CD-8BFD-31C224C361D6

P2860

New targets in psoriatic arthritis

http://www.wikidata.org/entity/Q28069592

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

New targets in psoriatic arthritis

@ast

New targets in psoriatic arthritis

@en

New targets in psoriatic arthritis

@nl

type

label

New targets in psoriatic arthritis

@ast

New targets in psoriatic arthritis

@en

New targets in psoriatic arthritis

@nl

prefLabel

New targets in psoriatic arthritis

@ast

New targets in psoriatic arthritis

@en

New targets in psoriatic arthritis

@nl

P1433

Q28069592-CAE7ABC5-CC56-4CFC-B6F9-358613ABF78E

P1476

Q28069592-DBFED05A-3D8A-4AE7-BBB7-0FC5DD97730B

P2093

Q28069592-3E870FE3-15DB-4FB7-B5D9-FABB8772B64B

P2860

Q28069592-044BEEEF-647B-4A65-A4FE-DE02B995AA91

Q28069592-17235478-7969-4E64-973C-82C79443B92A

Q28069592-17E7D1B4-EACA-465E-9851-3C1ED593603F

Q28069592-245C6611-E287-45DD-8010-25C13EB4D974

Q28069592-287BE787-DFC1-45F4-8D49-754E887FF1AC

Q28069592-334C498E-1BD2-4666-AE39-C4793A3AB782

Q28069592-3E0EF120-67C9-4D04-89BA-624054744F1C

Q28069592-403BCC16-46D2-4FB8-820D-6EA064656EB2

Q28069592-408D3F88-01E8-4DA6-AF69-EC62E8C5C115

Q28069592-4153A7ED-7C6B-413C-810A-0F339A9311BF

P304

Q28069592-ED475293-6FED-4397-9397-BFC90F94564F

P31

Q28069592-BB9569E7-2EA9-4701-8958-4FEEB31AE170

P356

Q28069592-A77E8670-DEE0-4057-9F29-744E25956BE0

P407

Q28069592-6A1510B2-9B6D-4602-92ED-353481AD9F5B

P433

Q28069592-0C171FAE-3EFE-43B4-8CBD-8F24682BEC60

P478

Q28069592-9347C3D8-AFF2-4D8C-B725-D3977DE43354

P577

Q28069592-996041D2-8B89-4265-8A14-EE968E3685C2

P698

Q28069592-0E4C0ED8-01D1-48E1-8015-529BA5A5ACF1

P356

P1433

P1476

New targets in psoriatic arthritis

@en

P2093

Juergen Braun

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

P304

ii30-ii37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEW343

http://www.w3.org/2001/XMLSchema#string

P407

P433

suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27856658

http://www.w3.org/2001/XMLSchema#string